Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670837 · ClinicalTrials.gov registry record · NA
Study of Cellutome System for Treatment of Individual Lesions in EB Pts
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT02670837 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 34 participants.
The verdict
NCT02670837, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
Few but persistent wounds often remain even after successful hematopoietic cell transplantation for systemic genodermatosis epidermolysis bullosa (EB). The investigators propose local wound therapy using epidermal skin grafting from the same donor that provided the hematopoietic graft, or from the same EB individual with a mosaic (naturally gene corrected) skin. In both cases permissive immune system and skin chimerism is expected to enable long-term epidermal engraftment and wound healing. The investigators will use FDA approved vacuum device (CelluTome®, Regulation number 878.4820) that enables scar-free harvesting of epidermis and its transfer on a non-adherent silicone dressing (Adaptic) to the recipient as a wound dressing.
Interventions
- DEVICE Cellutome Epidermal Harvesting System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-08-04 |
| Est. Completion | 2024-04-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670837
The ClinicalTrials.gov registry entry for NCT02670837 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cellutome Epidermal Harvesting System is the first listed.
NCT02670837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02670837 about?
NCT02670837 is a clinical study titled "Study of Cellutome System for Treatment of Individual Lesions in EB Pts". Few but persistent wounds often remain even after successful hematopoietic cell transplantation for systemic genodermatosis epidermolysis bullosa (EB). The investigators propose local wound therapy using epidermal skin grafting from the same donor that provided the hematopoietic graft, or from the s...
What is the current status of trial NCT02670837?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2016-08-04. Estimated completion is 2024-04-03.
What interventions are being tested in trial NCT02670837?
The interventions under investigation include: Cellutome Epidermal Harvesting System (DEVICE).
Who is sponsoring clinical trial NCT02670837?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.